Myfembree Tablet, Film Coated
Product Images NDC 72974-415

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Myfembree (NDC 72974-415). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sumitomo Pharma America, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Myfembree 01)

Chemical structure of relugolix, estradiol hemihydrate, and norethindrone acetate, depicted as a detailed molecular diagram showing atoms and bonds.*

FDA Label Image

Chemical Structure (Myfembree 02)

Chemical structure of estradiol hemihydrate, one of the active ingredients in Myfembree. The diagram shows the molecular arrangement including hydroxyl groups on the steroid framework.*

FDA Label Image

Chemical Structure (Myfembree 03)

Chemical structure of estradiol hemihydrate, one of the active ingredients in Myfembree. The diagram shows the molecular skeleton with labeled bonds and stereochemistry.*

FDA Label Image

Figure 1 L1 (Myfembree 04)

A line graph showing least squares mean percent change from baseline with 95% confidence intervals over 24 weeks. It compares two groups: MYFEMBREE (N=122), represented by a solid line with circles, and Placebo (N=113), represented by a dashed line with triangles. The MYFEMBREE group shows a greater percent decrease over time compared to the placebo group, which remains relatively stable.*

FDA Label Image

Figure 1 L2 (Myfembree 05)

A line graph comparing least squares mean percent change from baseline over 24 weeks between Myfembree and placebo groups. The y-axis shows percent change with confidence intervals, and the x-axis shows time points from baseline to week 24. The Myfembree group shows a marked decrease over time, while the placebo group remains relatively stable.*

FDA Label Image

Principal Display Panel (28 Tablet Bottle Label)

Label for Myfembree tablets containing relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg. The film-coated oral tablets are supplied in a package of 28 tablets. The label includes storage instructions, dosage directions to see prescribing information, and distributor details (Myovant Sciences, Inc, Brisbane, CA).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.